PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey
|
|
- Adrian McLaughlin
- 6 years ago
- Views:
Transcription
1 PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties 3rd - 6th November 2011, Barcelona, Spain
2 Flow Components of QoL Health related QoL Performance after Allo HSCT (BMT-SS) Children Performance after AutoHSCT Intervention? Possible How to run a study? Take home messages, future, general summary
3 Components of QoL Global QoL Physical (Fatigue, Pain) Emotional (Anxiety, Depression) Social (Family, friends) Functional (Work, sleep) Spiritual (religion, meaning) in HSCT, SJ Lee, QoL issues post tx.,
4 HRQoL: rısk factors changes according tıme Bevans, ASH Ed. Book, 2010
5 performance after allo hsct
6 Impact of different post-remission strategies on QoL in patients with AML German AML-Intergroup, survey on QoL with a RFS> 5 years after 1st Tr 419 of 818 patients (51.2%) median age: 42 years, and the med. f/u: 8 years EORTC QoL C allohct, 49 autohct in CR1; 249 CCT Haematologica 2008; 93:
7 Impact of different post-remission strategies on QoL in patients with AML German AML-Intergroup, survey on QoL with a RFS> 5 years after 1st Tr 419 of 818 patients (51.2%) median age: 42 years, and the med. f/u: 8 years EORTC QoL C allohct, 49 autohct in CR1; 249 CCT Haematologica 2008; 93:
8 Impact of different post-remission strategies on QoL in patients with AML Haematologica 2008; 93:
9 Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease Bone Marrow Transplant. 2010; 45:
10 Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease N=100, allo HSCT. Utility of three instruments recommended by the NIH; SF-36, the distance walked in 2 min, Lee chronic GVHD symptom bother scale. Results: Functional performance, measured by the SF-36 physical component summary score, was substantially lower (mean = 36.8±10.7) than the US population norm of 50 (P<0.001). The most severe decrements were in physical function (mean = 38.8±10.9) and physical role function (mean= 37.88±11.88) Bone Marrow Transplant. 2010; 45:
11 Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease Bone Marrow Transplant. 2010; 45:
12 bone marrow transplant survivor study (bmt-ss) A collaboration between City of Hope Cancer Center (and the University of Minnesota, established in 2000 Aim: To evaluate outcomes in a cohort of individuals with a diagnosis of cancer or other life-threatening illness Eligibility criteria: 1. HCT for hematologic and non-hematologic malignancies and other life-threatening disorders; 2. Date of transplantation between 01/ / Survival of 2 years or longer after HCT regardless of disease and SCT PIs: S. Bathia, D. Weisdorf Publications: 17 papers, since 2004
13 Impact of cgvhd on the health status of hematopoietic cell transplantation survivors: a report from the BMT-SS N=584 Blood. 2006;108:
14 Impact of cgvhd on the health status survivors: a report from the BMT-SS
15 functional status of long-term survivors: BMT-SS N=1479, >2 years post allohct. Med. age: 25.9 y Median f/u: 9.5 y. HCT survivors difficulty in holding jobs ([OR] 13.9) in obtaining health (OR: 7.1) or life (OR: 9.9) insurance compared with siblings (N=319) Blood. 2007;110:
16 Letter: very long-term survivors after HSCT Basel Group N=44, paired controls. f/u: 17.5 y physical health status can be impaired, while mental health preserved Blood. 2008;111:1740
17 Functional status limitations among survivors, overall and by diagnosis, compared to siblings: BMT-SS N= 401 (AML/ALL), siblings of participants (n=319) are controls Med age: 36.5 yr survivors/ 44yr siblings. Med. f/u: 8.4 yr. Conditioning included TBI in 86% of AML and 100% of ALL subjects. Compared to siblings, survivors had a higher frequency of exercise induced shortness of breath (DOI), neurosensory impairments, and problems with balance, tremor or weakness. M-V analysis, the risk did not differ by diagnosis. Abnormal sense of touch (OR 2.6, p=0.02) and to report their overall health as fair or poor (OR 2.2, p=0.03). (OP x3, DM x4) Conclusion: Ongoing surveillance for LEs and appropriate interventions are required to improve the health Leukemia. 2010; 24:
18 functional status limitations among survivors, overall and by diagnosis, compared to siblings: BMT-SS Leukemia. 2010; 24:
19 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
20 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS N=1065 (69%) 56% Allo HCT Blood. 2011;118:
21 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
22 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
23 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
24 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
25 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
26 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
27 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
28 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118:
29 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS presence of active chronic GVHD were associated with a 2-fold increased risk for somatic distress. 7% of the HCT survivors expressed suicidal ideation; patients with higher scores on depression subscale were most vulnerable Somatic distress is the biggest challenge Blood. 2011;118:
30 Adverse psychological outcomes in long-term survivors of HCT: BMT-SS presence of active chronic GVHD were associated with a 2-fold increased risk for somatic distress. 7% of the HCT survivors expressed suicidal ideation; patients with higher scores on depression subscale were most vulnerable Somatic distress is the biggest challenge Blood. 2011;118:
31 Chıldren
32 Performance Limitations and Participation Restrictions Among Childhood Cancer Survivors Treated With HCT
33 Performance Limitations and Participation Restrictions Among Childhood Cancer Survivors Treated With HCT N=235 age<21, alive >2 years, BMT-SS Arch Pediatr Adolesc Med. 2005;159:
34 performance after Auto HSCT&HDCT
35 Quality of life and rehabilitation in social and professional life after AHSCT&HDCT C-S, n=391, 12 y.s, 78% ASCT: significant, unfavourable impact on QoL (reintegration into social and professional life). Most symptoms and scores returned to N 3-6 years. Employment status and QoL were similar in patients who participated or not Annals of Oncology 13: , 2002
36 ıs Intervention possıble?
37 A randomized trial on the effect of a multimodal intervention on physical capacity, functional performance and QoL in adult patients undergoing allosct Randomized controlled trial Aim: investigate the effect of a 4- to 6-week multimodal program of exercise, relaxation and psychoeducation Physical capacity, Functional performance and QoL in allo-hsct N=42, adult pat.s 1st end point: aerobic capacity measured in VO2 max. 2nd end points: muscle strength, functional performance, physical activity level, QoL, fatigue, psychological wellbeing and clinical outcomes. Bone Marrow Transplantation (2009) 43,
38 A randomized trial on the effect of a multimodal intervention on physical capacity, functional performance and quality of life in adult patients Table 1 Multimodal intervention: exercise, progressive relaxation and psychoeducation Mode Frequency Intensity Duration Progression Stationary cycling 5 days/week Low to moderate: 50 75% HR max, RPE 10 13, MET min/session rest intervals as needed Dynamic and 5 days/week Dynamic: 1 2 sets, reps min/session stretching exercises Static: 1 set, hold for s MET 3.5 Resistance training 3 days/week Low to moderate: 1 2 sets of reps, min/session RPE 10 13, MET 3 Progressive relaxation 2 days/week Low: RPE 6 9, MET min/session Psychoeducation Ongoing Increased intensity and duration ¼ ¼ ¼ ¼ Bone Marrow Transplantation (2009) 43,
39 Intervention: possıble! Multimodal Intervention with aerobic, resistance and active exercises, progressive relaxation and psychoeducation; sustained 1- aerobic fitness, 2- muscle strength and 3- minimized loss of functional performance, favored the intervention group, but did not reach statistical significance. no untoward events sustained aerobic capacity and muscle strenght reduced loss of functional performance Bone Marrow Transplantation (2009) 43,
40 AIM: Effectiveness of an individualized high intensity strength and interval training program with respect to physiological and psychological health status PATs: MM & NHL, ASCT&HDCT, N=120, incl.period 2 y. METHODs: Multicenter, prospective, single blind randomized controlled trial will be performed. (1) intervention plus usual care; or (2) usual care. The intervention consists of an18-week individualized supervised high-intensity exercise program and counselling. The primary outcomes: cardiorespiratory fitness, muscle strength and fatigue) and secondary outcomes are assessed at BL, completion of the intervention and at 12 mo.s BMC Cancer 2010, 10:671
41 How to run a study?
42 Function, Adjustment, Quality of Life and Symptoms (FAQS) in Allo HSCT Survivors: A Study Protocol Aim: 1. explore the patterns of change in these health outcomes during the survivorship phase 2. characterize subgroups of survivors experiencing adverse outcomes 3. Examine relationships among outcomes and demographic 4. clinical factors (such as age, graft-versus-host disease (GVHD), and disease relapse) Health and Quality of Life Outcomes 2011, 9:24
43 Function, Adjustment, Quality of Life and Symptoms (FAQS) in Allo HSCT Survivors: A Study Protocol Methodology: Longitudinal observational study, adults, who >3 y post Allo HSCT, Qs annually. Demographic and clinical data with a series of patient-reported outcome measures, specifically: 1) Medical Outcomes Study SF- 36; 2) Functional Assessment of Chronic Illness Therapy (FACIT) - General 3) FACIT-Fatigue; 4) FACIT- Spiritual; 5) Psychosocial Adjustment to Illness Scale; 6) Rotterdam Symptom Checklist-Revised 7) Pittsburgh Sleep Quality Index. Health and Quality of Life Outcomes 2011, 9:24
44 Sample: fact-g /vrs. 4)
45 Current status conclusıon future prospects last words
46 Chronic Health Condıtıons
47 Health Care Utilization by Adult Long-term Survivors of HCT : BMT-SS Report HCU: general contact with health care system, general physical examination, and cancer/hct related visit N=845, f/u: 6 ys. Conclusion: need for increased awareness of the LT f/u needs of the HCT survivors by the health care providers Cancer Epidemiol Biomarkers Prev 2007;16: 834 9
48 Health Care Utilization by Adult Long-term Survivors of HCT : BMT-SS Report HCU: general contact with health care system, general physical examination, and cancer/hct related visit N=845, f/u: 6 ys. Conclusion: need for increased awareness of the LT f/u needs of the HCT survivors by the health care providers Cancer Epidemiol Biomarkers Prev 2007;16: 834 9
49 Current STATUS on QoL related performance Bevans, ASH Ed. Book, 2010
50 take home message for clinicians-i
51 take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!!
52 take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!! 1- Patients should be counseled: disease-specific and treatment-specific risks for TR morbidity and mortality, acute and cgvhd, infectious complications, primary disease relapse, and late complications of transplantation.
53 take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!! 1- Patients should be counseled: disease-specific and treatment-specific risks for TR morbidity and mortality, acute and cgvhd, infectious complications, primary disease relapse, and late complications of transplantation. Information: Complications can result in worsened QoL.
54 take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!! 1- Patients should be counseled: disease-specific and treatment-specific risks for TR morbidity and mortality, acute and cgvhd, infectious complications, primary disease relapse, and late complications of transplantation. Information: Complications can result in worsened QoL. 2- GOOD NEWS: greater than 60% of transplant survivors report their QOL as good to excellent and greater than 60% have no major functional limitations.
55 take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!! 1- Patients should be counseled: disease-specific and treatment-specific risks for TR morbidity and mortality, acute and cgvhd, infectious complications, primary disease relapse, and late complications of transplantation. Information: Complications can result in worsened QoL. 2- GOOD NEWS: greater than 60% of transplant survivors report their QOL as good to excellent and greater than 60% have no major functional limitations. 3- BAD NEWS: following adverse outcomes: >25% of survivors will have ongoing significant medical problems and >25% experience emotional distress and impaired life satisfaction. Stated differently, at least 25% of survivors have ongoing bothersome symptoms.
56 take home message for clinicians-ii Blood. 2009;114:7-19
57 take home message for clinicians-ii Transplant physicians should consider performance as secondary to the curative potential of HCT, not underestimate patients symptoms, and overestimate their QoL and HR performance. Blood. 2009;114:7-19
58 take home message for clinicians-ii Transplant physicians should consider performance as secondary to the curative potential of HCT, not underestimate patients symptoms, and overestimate their QoL and HR performance. Increased awareness is needed regarding the impact of HCT on performance and the importance of QoL to patients. Blood. 2009;114:7-19
59 take home message for clinicians-ii Transplant physicians should consider performance as secondary to the curative potential of HCT, not underestimate patients symptoms, and overestimate their QoL and HR performance. Increased awareness is needed regarding the impact of HCT on performance and the importance of QoL to patients. Use update literature to help your patients to make informed decisions. Blood. 2009;114:7-19
60 Future Prospects
61 Future Prospects Long-term impact of resolved cgvhd
62 Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS
63 Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS Impact of RIC regimens,
64 Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS Impact of RIC regimens, Predictors of Functional health status after HCT
65 Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS Impact of RIC regimens, Predictors of Functional health status after HCT Establish a Cohort with collaboration of interested centers within EBMT
66 Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS Impact of RIC regimens, Predictors of Functional health status after HCT Establish a Cohort with collaboration of interested centers within EBMT Performance of the team, physician???
67 KEY ISSUES To understand the contribution of pre-hsct exposures, HSCTrelated exposures and comorbidities in the development of adverse events. It is necessary to identify those at highest risk of complications. There is a need to develop intervention strategies. Long-term follow-up guidelines need to be disseminated and refined. Expert Rev. Hematol. 2011; 4:
68 KEY ISSUES To understand the contribution of pre-hsct exposures, HSCTrelated exposures and comorbidities in the development of adverse events. It is necessary to identify those at highest risk of complications. There is a need to develop intervention strategies. Long-term follow-up guidelines need to be disseminated and refined. Expert Rev. Hematol. 2011; 4:
Late complications after hematopoietic stem cell transplant in adult patients
Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity
More informationSurvivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life
1 Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life Stephanie J. Lee, MD, MPH Fred Hutchinson Cancer Research Center April 16, 2016 (40 min) Hematopoietic
More informationLate effects after HSCT
Late effects after HSCT Yves Chalandon Hematology Division, University Hospital of Geneva (HUG) Switzerland Hôpitaux Universitaires de Genève Company name Disclosures of: Yves Chalandon Research support
More information4nd Patient and Family Day
4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationEBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation
EBMT EBMT Organisation and Activities J Apperley 13th. ESH-EBMT Training Course Targu Mures May 24 26, 2010 History Organisation Studies Activity Philosophy EBMT Website www.ebmt.org EBMT Society European
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationWorkshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan
Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationAML:Transplant or ChemoTherapy?
AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationSKIN CANCER AFTER HSCT
SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationOutcome of patients with hematologic malignancy admitted to the ICU
Outcome of patients with hematologic malignancy admitted to the ICU Geeta Mehta MD, FRCPC Mount Sinai Hospital Toronto, Canada CCCF November 2, 2016 Disclosures Hematologic Malignancy Advances in diagnostics,
More informationSurvivorship After Stem Cell Transplantation and Long-term Followup
Survivorship After Stem Cell Transplantation and Long-term Followup Navneet Majhail, MD, MS Director, Blood & Marrow Transplant Program, Cleveland Clinic Professor, Cleveland Clinic Lerner College of Medicine
More informationProtecting Your Health After Transplant (Adults)
Protecting Your Health After Transplant (Adults) Navneet Majhail, MD, MS Medical Director, Health Services Research, National Marrow Donor Program Adjunct Associate Professor of Medicine, University of
More informationLate Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor
Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor Saro Armenian, DO, MPH Associate Professor, Departments of Pediatrics and Population Sciences Director,
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationShould patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy?
Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy? Pierre Fenaux Cohem 2012 Barcelona Should patients with higher risk MDS (or AML
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationStem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic
Stem cell Survivorship: Searching for a solution to our success Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic Location of Centers Participating in t he CI BMTR 2 0 0 7................................................................................................................
More informationOutline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT
Comorbidities before Allogeneic Hematopoietic Cell Transplantation (HCT) The HCT-specific Comorbidity Index (HCT-CI) Mohamed Sorror, M.D., M.Sc. FHCRC Seattle, WA Outline Pretransplant Essential data Why
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationLate effects, health status and quality of life after hemopoietic stem cell
Late effects, health status and quality of life after hemopoietic stem cell transplantation (HSCT) THE 13th ESH-EBMT TRAINING COURSE ON BLOOD AND MARROW TRANSPLANTATION EBMT Slide template Barcelona 7
More informationBrentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase
Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationCOHEM Barcellona 2012 Hemoglobinopathies debate
COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication
More informationPsychosocial Late Effects. of Childhood Cancer. Matt Bitsko, Ph.D Departments of Pediatrics and Psychology
Psychosocial Late Effects of Childhood Cancer. Matt Bitsko, Ph.D Departments of Pediatrics and Psychology Learning Objectives: The learner will be able to identify the most common psychosocial late effects
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationComparing outcome between Belgian haematopoietic stem cell transplant centres
ENCR2016, 2014/06/10 1 Comparing outcome between Belgian haematopoietic stem cell transplant centres Gilles Macq 1, Evelien Vaes 1, Geert Silversmit 1, Marijke Vanspauwen 1, Liesbet Van Eycken 1 & Yves
More informationDr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology
Advances in Autologous and Allogeneic Stem Cell Transplantation Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology April 12, 2014 Disclosures
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationAre We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017
Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care
More informationThe Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014
The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014 Worldwide Network for Blood and Marrow Transplantation Transplants A Little
More informationStem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -
Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationLate Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor
Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor Saro Armenian, DO, MPH Associate Professor, Departments of Pediatrics and Population Sciences Director,
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationLate Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT
Objectives Late Complications Navneet Majhail, MD, MS Review late complications in hematopoietic cell transplant (HCT) recipients Review screening and prevention guidelines for HCT survivors Review upcoming
More informationLate Complications. Navneet Majhail, MD, MS
Late Complications Navneet Majhail, MD, MS Medical Director, Health Services Research, NMDP Assistant Scientific Director, CIBMTR Adjunct Associate Professor of Medicine University of Minnesota Objectives
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationLate effects and long-term survivorship after HSCT
Late effects and long-term survivorship after HSCT André Tichelli What are late effects? Why is it of importance? How to proceed in daily routine? 59-year old male survivor 22 years after allogeneic HSCT
More informationRapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation
Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Subtitel Transplantation Boelens/Nierkens lab Jaap Jan Boelens, Central Immune
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More informationWhich is the best treatment for relapsed APL?
Which is the best treatment for relapsed APL? 7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, 2017 Eva Lengfelder Department of Hematology and Oncology University Hospital
More informationDisclosures of: Emanuele Angelucci
Company name Novartis Disclosures of: Emanuele Angelucci Research support Employee Consultant Stockholder Speakers bureau Advisory board Chair of TELESTO pro Other EBMT 2012 Educational Session Haemoglobinopathy
More informationYes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationNiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute Adult Umbilical Cord Blood Transplantation
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationLate Effects after Transplantation for Pediatric Severe Aplastic Anemia. Jean E. Sanders, M.D.
Late Effects after Transplantation for Pediatric Severe Aplastic Anemia Jean E. Sanders, M.D. Patient Characteristics Acquired Fanconi Number 137 15 Gender F:M 63:74 9:6 Etiology: Idiopathic Hepatitis
More informationImmunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience
36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationLong-Term Outcomes After Hematopoietic Cell Transplantation
Long-Term Outcomes After Hematopoietic Cell Transplantation Conflicts of Interest No relevant financial conflicts of interest Navneet Majhail, MD, MS Medical Director, NMDP Assistant Scientific Director,
More informationIl Trapianto da donatore MUD. Alessandro Rambaldi
Il Trapianto da donatore MUD Alessandro Rambaldi Overview Comparison of outcomes of allo- HSCT from matched related and unrelated donors. We need evidence based results! Is the Dme needed to find an unrelated
More informationBlood & Marrow Transplantation Center
Blood & Marrow Transplantation Center We were one of the first centers in the world to routinely offer patients blood and marrow transplantation (BMT). What Sets Us Apart High-volume center performs about
More informationDisclosure. Objectives 1/22/2015
Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationLate effects and quality of life after haematological stem cell transplantation
Late effects and quality of life after haematological stem cell transplantation Prof. dr hab. Ewa Gorczyńska Zofia Lutrowicz Department of Pediatric Hematology Oncology and Bone Marrow Transplantation,
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationFeasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years
The Open Leukemia Journal, 2010, 3, 55-59 55 Open Access Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than Years
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More information"Chemotherapy based stem cell mobilization: pro and con"
"Chemotherapy based stem cell mobilization: pro and con" Mohamad MOHTY Clinical Hematology and Cellular Therapy Dpt. Sorbonne Université Hôpital Saint Antoine Paris, France Disclosures Sponsorship or research
More informationDisclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
ALL in AYAs: Health Outcomes as a Criterion for Selecting Optimal Therapy David R. Freyer, DO, MS Director, Survivorship and Supportive Care Program, Children s Center for Cancer and Blood Diseases, Children
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Policy Number: 8.01.32 Last Review: 7/2018 Origination: 7/2002 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationSummary. Ladislav Slovacek 1,2 ABCDE, Birgita Slovackova 3 ABCD, Vladimir Pavlik 4 DEFG, Ladislav Jebavy 1,5 DEFG
Rep Pract Oncol Radiother, 27; 12(4): 231-238 Original Paper Received: 27.5.7 Accepted: 27.7.9 Published: 27.8.31 Authors Contribution: A Study Design B Data Collection C Statistical Analysis D Data Interpretation
More informationoptions in Myeloablative HSCT
Should Busilvex we use AlloSCT in AML options in Myeloablative HSCT Reduced Intensity or Myeloablative preparative protocols? Moderator: Andrea Bacigalupo Reduced Intensity: Arnon Nagler Myeloablative:
More informationADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES
ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES Corey Cutler, MD MPH FRCPC Associate Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute, Boston, MA HCT Outcomes - MDS 2001-2011
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationGetting Fit for Transplant. Thuy Koll, MD Assistant Professor Division of Geriatrics Department of Internal Medicine
Getting Fit for Transplant Thuy Koll, MD Assistant Professor Division of Geriatrics Department of Internal Medicine No Disclosures. Objectives Describe frailty in transplant Discuss the role of physical
More informationStem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT
Stem cells -Dr Dinesh Bhurani, MD, DM, FRCPA -Director, Department of Haematology and BMT Rajiv Gandhi Cancer Institute, Delhi, Flow of presentation Update on stem cell uses Haematopoietic stem cell transplantation
More informationTHE LEUKEMIAS. Etiology:
The Leukemias THE LEUKEMIAS Definition 1: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues Definition 2: Heterogenous
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More information